BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years

We recently published a list of 10 Stocks That Will Make You Rich In 3 Years. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other stocks that will make you rich in 3 years.

Is the Bull Market Over?

The stock market has been facing volatility since the tariffs were announced. This has created fears of a recession, leading many investors to think that this might be the end of the bull market. On April 29, Andrew Simmon, Head of Applied Equity Advisor Team at Morgan Stanley Investment Management, released a note explaining that the bull market may not have finished yet.

Simmon noted that the stock market took big swings earlier this year, which has hampered investor enthusiasm. However, this also presents a better outlook as compared to the start of the year, as now the bullish side of the market is weighing less. Simmon believes that this presents an attractive buying opportunity to get into the market at fairly discounted prices. He highlighted that the investment management firm had already anticipated 2025 to be a pause year for the S&P 500, with single-digit gains for investors. The third year of bull markets is usually mediocre, however, it still has the potential to produce single-digit gains, with greater volatility.

The Head of Applied Equity team highlighted that volatility has been one of the main characteristics of the market since the announcement of planned global tariffs. He noted that a decline of 20% from the peak would have indicated a bull market, however, the market pulled back and gained 10% on April 9, after the announcement of some tariffs being pulled back. Citing a statistical study, Simmon noted that according to an analysis, 9 out of 12 times when the S&P 500 has fallen more than 20%, it has brought a recession along with it. However, under the current situation, it seems that the “Trump Put” came into play as the recession talks started to spur the market.

While explaining the investment thesis for volatile times, Simmons acknowledged that investing in these times can be stressful, however, the key here is to follow the pattern as a guide. The pattern shows that when the S&P 500 is down 15%, it is a good time to enter the market. He explained that the S&P 500 has fallen 15% around 18 times since 1950, and the one-year return after the drop has been 14%, thereby making it an attractive entry point. Simmon concluded by noting that although there is no guarantee, however, historic trends have shown that when the markets go down, it is a good time to move against the headlines and increase stake in equities. This is because, as per the trends, a downturn often indicates that the odds of getting greater returns are getting better.

Our Methodology 

To curate the list of 10 stocks that will make you rich in 3 years, we used financial media reports and compiled a list of 30 stocks. We then ranked them in ascending order of the analyst upside potential sourced from CNN. We have also added the hedge fund sentiment around each stock, as of Q4 2024. Please note that the data was recorded on May 4, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Hedge Fund Holders: 51

Analysts Upside Potential: 55.57%

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is an international biopharmaceutical company that develops and commercializes targeted therapies addressing the root causes of rare genetic conditions. It primarily focuses on treating lysosomal storage disorders, achondroplasia, severe hemophilia A, Batten disease, and phenylketonuria.

On May 2, Analyst Phil Nadeau of TD Cowen maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), setting a price target of $120. The company achieved a revenue of $745 million, reflecting a 15% increase year-over-year and surpassing expectations. The analyst noted that the growth was largely driven by a 40% increase in Voxzogo revenue, reflecting high demand and new patient initiations across all regions. Moreover, the company’s operating margin expanded to 36%, supporting a significant bottom-line beat. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has reaffirmed its 2025 guidance, projecting revenues of $3.1 billion to 3.2 billion and non-GAAP EPS between $4.20 and $4.40. It is the best stock that will make you rich in 3 years.

Overall, BMRN ranks 1st on our list of stocks that will make you rich in 3 years. While we acknowledge the potential of BMRN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BMRN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.